PSMA PET/CT for prostate cancer: what it finds that other scans miss

If you or your father or husband has prostate cancer, this is probably the scan that has been mentioned — and it is worth understanding why it has displaced the tests that came before it.

The target

Prostate cancer cells carry a protein on their surface called prostate-specific membrane antigen, or PSMA. It is present on the great majority of prostate cancer cells, and expression tends to increase as the disease becomes more aggressive.

That makes it an almost ideal imaging target. We use a small molecule designed to fit PSMA the way a key fits a lock, tagged with a short-lived radioactive marker — usually gallium-68, sometimes fluorine-18. Injected into a vein, it circulates and fastens on to prostate cancer cells wherever they are, and only to them.

The result is a whole-body map of where the disease actually is, rather than where enlarged structures happen to be.

Why it replaced the bone scan and CT

The old standard was a CT scan of the abdomen and pelvis plus a technetium bone scan. Both have real limitations.

A bone scan does not see prostate cancer. It sees the bone's reaction to a tumour — new bone laid down around a deposit. That reaction takes time to develop, and it also happens in arthritis, old fractures and degenerative disease, which is why bone scans produce so many equivocal results. And it says nothing at all about lymph nodes or soft tissue.

CT judges lymph nodes largely by size. A node under a centimetre is called normal. Prostate cancer frequently sits in nodes well below that threshold.

PSMA PET/CT sees the cancer cells themselves — in bone, in lymph nodes, in soft tissue, everywhere in one scan. Head-to-head studies have consistently shown higher accuracy than the CT-plus-bone-scan combination, and international guidelines have shifted accordingly for staging higher-risk disease.

The two situations where it is used

At diagnosis, for intermediate- and high-risk disease. The question is whether the cancer is confined to the prostate. If it is, surgery or radical radiotherapy can be curative. If it has already reached distant nodes or bone, an operation will not cure it, and putting a man through a prostatectomy that cannot achieve its purpose is a bad outcome that better imaging can prevent.

For rising PSA after treatment — biochemical recurrence. PSA should fall to near zero after a prostatectomy. If it starts climbing again, cancer has returned somewhere. The whole clinical problem is where. If it is a single node or one bone deposit, targeted radiotherapy can still be curative. If it is widespread, systemic treatment is the right answer. Conventional imaging is usually entirely normal at the PSA levels where this decision has to be made. PSMA PET frequently is not.

"My PSA is only 0.4 — is a scan worth it?"

This is the question we are asked most, and the answer is more often yes than people expect.

Detection rates rise with PSA, and are naturally lower at very low values — but PSMA PET has a meaningful detection rate even below 0.5 ng/mL. That is precisely the window in which finding a single site of recurrence can mean focused, potentially curative radiotherapy rather than lifelong hormone therapy.

Two other things influence the decision: how fast the PSA is rising (a short doubling time favours scanning) and whether the result would actually change what happens next. Your urologist or oncologist will weigh these with you.

What happens on the day

Straightforward, and easier than an FDG scan:

• No fasting. Eat and drink normally.
• Drink water, and empty your bladder just before the scan. The tracer is excreted in urine, and a full bladder can obscure disease immediately next to it.
• About an hour between injection and scan.
• Roughly 15 minutes on our digital scanner.
• Bring your PSA trend — the actual sequence of values with dates, not just the latest one — your biopsy and Gleason report, and any previous scans.
• Tell us if you are on hormone therapy (ADT) and when it started, as it changes how PSMA expression appears.

Reading the result

A few points that save unnecessary alarm.

Not every PSMA-avid spot is prostate cancer. PSMA is expressed normally in the salivary glands, kidneys, liver, spleen and small bowel — the report will note these as physiological. It is also expressed by some other tumours and, occasionally, in healing rib fractures and in Paget's disease of bone. Distinguishing these is the reporting radiologist's job, and it requires experience.

A negative scan does not always mean no disease. A small proportion of prostate cancers, particularly poorly differentiated or neuroendocrine-differentiated ones, do not express much PSMA. In these, an FDG PET may be added — and a tumour that is FDG-positive but PSMA-negative behaves very differently, which is clinically important information in itself.

The theranostics connection

This is where it becomes genuinely interesting.

The PSMA-targeting molecule can carry a therapeutic isotope instead of an imaging one. Attach lutetium-177 rather than gallium-68 and it delivers radiation directly to the cells it binds — treatment that seeks out prostate cancer wherever it has spread.

That approach, Lu-177 PSMA therapy, is now established for advanced disease that has stopped responding to hormone treatment. And the gatekeeper is the diagnostic scan: a PSMA PET/CT shows whether a man's disease takes up the molecule strongly enough to be worth treating this way.

See it, then treat exactly what you saw. It is the principle behind everything called theranostics, and it is why our own radionuclide therapy suite is the next thing we are building.

Where scanner quality comes in

PSMA findings are frequently very small — a 5 mm node beside a blood vessel, a subtle focus in a vertebra. Whether it is confidently reported or dismissed as equivocal depends on the resolution of the detector and the timing precision of the system.

That is the practical case for a digital scanner in this particular study: the finding that changes the treatment plan is often at the very limit of what the machine can resolve.

To discuss whether a PSMA PET/CT is appropriate in your case, call +91 93169 25516 — we are happy to talk it through with your treating urologist or oncologist.